266 related articles for article (PubMed ID: 34065284)
1. Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.
Dawsey SJ; Campbell SC; Ornstein MC
Curr Oncol; 2021 May; 28(3):1921-1926. PubMed ID: 34065284
[TBL] [Abstract][Full Text] [Related]
2. Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.
Iisager L; Ahrenfeldt J; Donskov F; Ljungberg B; Bex A; Lund L; Lyskjær I; Fristrup N
BMC Cancer; 2024 Feb; 24(1):260. PubMed ID: 38402173
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.
Yoshino M; Ishihara H; Nemoto Y; Nakamura K; Nishimura K; Tachibana H; Fukuda H; Toki D; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Jpn J Clin Oncol; 2022 Oct; 52(10):1208-1214. PubMed ID: 35780441
[TBL] [Abstract][Full Text] [Related]
4. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.
Hatakeyama S; Naito S; Numakura K; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Tsushima E; Nishiyama H; Ito A; Kojima Y; Habuchi T; Obara W; Tsuchiya N; Ohyama C
Int J Urol; 2021 Apr; 28(4):369-375. PubMed ID: 33314387
[TBL] [Abstract][Full Text] [Related]
5. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
6. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.
Studentova H; Rusarova N; Ondruskova A; Zemankova A; Student V; Skanderova D; Melichar B
Curr Oncol; 2022 Aug; 29(8):5475-5488. PubMed ID: 36005171
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Margulis V; Matin SF; Wood CG
Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
[TBL] [Abstract][Full Text] [Related]
8. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
9. Surgical and focal treatment for metastatic renal cell carcinoma: A literature review.
Naito S; Kato T; Tsuchiya N
Int J Urol; 2022 Jun; 29(6):494-501. PubMed ID: 35340081
[TBL] [Abstract][Full Text] [Related]
10. Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinoma.
Reese SW; Eismann L; White C; Villada JA; Khaleel S; Ostrovnaya I; Vazquez-Rivera K; Carlo MI; Feldman D; Lee CH; Motzer R; Voss MH; Kotecha RR; Matulewicz RS; Goh A; Coleman J; Russo P; Hakimi AA
Urol Oncol; 2024 Feb; 42(2):32.e9-32.e16. PubMed ID: 38135627
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy in the era of targeted therapies: a review.
Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
[TBL] [Abstract][Full Text] [Related]
12. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
13. Radical Nephrectomy After Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma.
Yanagisawa T; Schmidinger M; Kawada T; Bekku K; Kimura T; Shariat SF
Eur Urol Focus; 2023 Mar; 9(2):275-277. PubMed ID: 36775716
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
16. Role of cytoreductive nephrectomy in renal cell carcinoma.
Chiong E; Wood CG; Margulis V
Future Oncol; 2009 Aug; 5(6):859-69. PubMed ID: 19663735
[TBL] [Abstract][Full Text] [Related]
17. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
[TBL] [Abstract][Full Text] [Related]
18. The role of cytoreductive nephrectomy in the immuno-oncological therapy era.
Magee DE; Helstrom E; Kutikov A
Curr Opin Urol; 2023 Mar; 33(2):136-141. PubMed ID: 36710594
[TBL] [Abstract][Full Text] [Related]
19. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
[TBL] [Abstract][Full Text] [Related]
20. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
